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As per the 2007 Global Malaria Eradication Plan, malaria
transmission blocking is seen as key to malaria elimina-
tion strategies. A highlight that has emerged from game-
tocytocidal assays to identify novel compounds with
malaria transmission blocking ability is that, unlike asex-
ual-based assays, greater variability in end-point readout
may exist between these assays that interrogate different
parasite biological functions. Drug mode-of-action is
likely to be an important factor on this outcome. Such
variability may be mitigated by screening compounds
based on similar pharmacophores in series. One of the
major concerns with the current assay platforms is their
inability to be robustly used to screen variant pharmaco-
phores accurately as the different assay principles may
interrogate different biological functions. As such, com-
pounds targeting a specific biological pathway may in
extreme cases either fail in a certain assay, or by contrast,
may be flagged as false positives. Taking assay platform
differences into account, and relying on good intra-assay
variability for each assay optimized in our laboratories,
the ATP, pLDH, luciferase reporter and PrestoBlue™
assays were compared in context of a blinded MMV
10-compound set. All the assays were performed in par-
allel on the same gametocyte population (except for the
luciferase reporter lines). The remaining parameters for
each assay were all comparable. In each case, the assay
was performed for 48 h of continuous drug pressure for
at least three replicates. Although direct comparison of
absolute inhibition values are difficult between assay plat-
forms, similar trends were observed including compara-
tive performance of the luciferase marker assay and the
PrestoBlue™ assay for e.g. DHA and Methylene blue.
Interestingly, the ATP assay could not detect any inhibi-
tory activity for some quinoline family members and may
therefore be more sensitive in indicating the inability of
these compounds to inhibit gametocytes. Data from the
luciferase reporter assays for these compounds indicate
that the compounds are indeed more active against early
stage gametocytes. The signal obtained for these com-
pounds in the PrestoBlue™ and pLDH assays may there-
fore rather reflect the inability of these assays in
discriminating activity of compounds against earlier
stages of gametocytes, whereas the ATP assay more accu-
rately reflect these compounds’ activity. Whilst this data
is informative from a biological perspective and may pro-
vide indications of the drug mode of action, it does high-
light the care that has to be taken in screening platforms
where compounds may be falsely assigned activity (or
lack thereof) based on a single assay.
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